Media About Us
RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.
The Russians are back. After capturing the attention of the nanobio crowd with a few hefty investments in the U.S., RusNano is now partnering with Domain Associates on a $760 million initiative that will invest in about 20 life sciences companies and construct a pharma manufacturing center in Russia to produce next-gen therapies.
Russian Nanotechnologies Corp. plans to work with Domain Associates, a U.S. venture fund, to invest $760 million in U.S. life science companies and build facilities in Russia.